NeuroVentures Capital LLC

Description

Cytyc Corporation is a leading women's health company that designs, develops, manufactures, and markets innovative and clinically effective products. Cytyc products cover a range of women's health applications, including cervical cancer screening, breast cancer risk assessment, and treatment of excessive menstrual bleeding. The ThinPrep(R) System is the most widely used method for cervical cancer screening in the United States .

Acumen Pharmaceuticals Inc. (www.acumenpharm.com) is a venture-backed, pre-clinical biotech company, focused on developing the first effective therapeutics and diagnostics for Alzheimer's disease and other memory-related disorders. Founded in 1996, Acumen owns or has licensed the critical patents underlying the ADDL mechanism now widely believed to cause Alzheimer's disease. In addition to an ELISA-based diagnostic, Acumen has several therapeutic approaches to stop ADDL-related diseases. NeuroVentures LLC has made a seed investment in the Company.

Based in Alpharetta , Ga. , Proxima Therapeutics, Inc. is a privately held medical device company established in 1995 to develop site-specific cancer treatment systems for breast and brain tumors. Products include GliaSite RTS for brain cancer and MammoSite RTS for breast cancer. Additional information is available on the company’s Web site at www.mammosite.com. Physicians and patients may call 1-86-MAMMOSITE (1-866-266-6748) for more information.

Saegis Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on developing medicines that protect and enhance the function of the human mind, today announced that it has been granted an exclusive license to develop and market its lead Alzheimer’s disease candidate, SGS742, from Novartis Pharma AG. Under the terms of the agreement, Novartis received an equity stake in Saegis.

Companies nearby